Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update. - Wikidata - wikimedia - TriplyDB

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.

http://www.wikidata.org/entity/Q38028619

about

Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab.Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.Activation of the JAK/STAT pathway in Behcet's disease.Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population.Protein kinase CK2 governs the molecular decision between encephalitogenic TH17 cell and Treg cell development.Using EAE to better understand principles of immune function and autoimmune pathology Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.Recent advances in Takayasu arteritis.Revisited HLA and non-HLA genetics of Takayasu arteritis--where are we?Late reaction to ustekinumab infusion.Biological therapy induces expression changes in Notch pathway in psoriasis.The localisation of the heparin binding sites of human and murine interleukin-12 within the carboxyterminal domain of the P40 subunit

P2860

Q33800651-BA7A0222-D8B3-42C6-992E-1A7B5B941F46 Q34763844-18D72255-7B26-41E7-BD45-B497B9EF883B Q35647068-E3708369-0877-4E06-A445-BA6037EA5405 Q36367126-CC354C12-9BC2-417F-AAD6-935F9BF34497 Q37083408-D08F99EA-5287-491F-8D9C-E263BF47CDC2 Q37247661-75536064-6252-41ED-B799-B60CF5F7C860 Q37657501-BE5E8E86-24CE-4AA6-82CC-089EF2F107B0 Q38150110-90365D83-4F5D-4E8F-8697-FEACAA21E42A Q38174167-920B90A1-7D72-4A60-8705-E4BA958DF752 Q38189191-D29F9F99-2887-4640-805B-C6B520C7B354 Q38547821-C21EFC5D-BE57-4280-B3B8-01470018A464 Q42879699-538459A1-14C1-409E-975E-381E09F09E23 Q53368019-E362B4D0-986B-40DA-A772-B751FC5EA64D Q58794936-7C9A2921-78EF-47EB-845A-AEB46D775F11

P2860

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.

http://www.wikidata.org/entity/Q38028619

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Development of the IL-12/23 an ...... uture perspectives--an update.

@en

type

label

Development of the IL-12/23 an ...... uture perspectives--an update.

@en

prefLabel

Development of the IL-12/23 an ...... uture perspectives--an update.

@en

P1433

Q38028619-119CF0E5-24F0-4DEE-AA7D-E673B082C06E

P1476

Q38028619-79BC6DFC-FB26-4D8A-8B76-104FBD95A8DA

P2093

Q38028619-12AD1538-4316-443F-A93D-3CD0F1AC57EC

Q38028619-35C44DD4-04DD-46E2-92E1-0B75C64D0609

Q38028619-3671256A-42D9-4111-93EF-076D2D28BEA3

Q38028619-57FBE936-2BAE-479B-8F95-E5893542DF68

Q38028619-6AE59AE9-6344-481A-954C-378E6A86D94D

Q38028619-7DC32E80-3FA0-4998-89E6-11ACBA31BC1D

Q38028619-97A49B4B-1937-4228-9E2D-151FDC8C075E

Q38028619-A635FC76-6DCA-4969-987A-CAA7F28A749F

Q38028619-C686F927-7158-449C-A7F4-C0B3D70DAF59

Q38028619-D8431E9E-8680-4124-9F90-DC39CFDA5B6D

P2860

Q38028619-06F15A82-3002-4700-8862-F59496B25DD2

Q38028619-2D99F7FB-A982-4BC2-B998-CC527350B573

Q38028619-3C05E266-B816-428E-B6C6-F00731F16B13

Q38028619-9293F992-DA25-4CDE-BBCA-FF26814FAD3A

Q38028619-9A44BC83-CB2E-4911-A4A4-442F84802588

Q38028619-9F4095C0-FC92-40EC-8735-D377CF44C076

Q38028619-F21FD090-D791-4E1C-8466-1176AA30AE62

Q38028619-FE91CE80-2FC6-46DF-9B49-EC598A02959C

P304

Q38028619-97FB5B28-8954-4A47-9EB5-83697EB180A7

P31

Q38028619-CB02982C-0F23-4FE7-8AA5-455B1D9D14E7

P356

Q38028619-91DAD106-CFAB-4F26-8A20-5764D62ABDCD

P407

Q38028619-91A19F9B-EB67-41F2-9790-EA455B3E577A

P478

Q38028619-3ED49282-BCB3-4ACB-9A97-CF429F43084B

P577

Q38028619-BBABB97B-FB67-498D-A700-9DB278DA1E70

P698

Q38028619-9B838397-F140-4F1B-9109-B4DA3423D9EB

P356

J.1749-6632.2012.06670.X

P1433

Annals of the New York Academy of Sciences

P1476

Development of the IL-12/23 an ...... uture perspectives--an update.

@en

P2093

Brad Schenkel

http://www.w3.org/2001/XMLSchema#string

Carrie Brodmerkel

http://www.w3.org/2001/XMLSchema#string

Cynthia Guzzo

http://www.w3.org/2001/XMLSchema#string

Honghui Zhou

http://www.w3.org/2001/XMLSchema#string

Jacqueline Benson

http://www.w3.org/2001/XMLSchema#string

Jill Giles-Komar

http://www.w3.org/2001/XMLSchema#string

Kavitha Goyal

http://www.w3.org/2001/XMLSchema#string

Mary Ann Mascelli

http://www.w3.org/2001/XMLSchema#string

Michael Plotnick

http://www.w3.org/2001/XMLSchema#string

Newman Yeilding

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.

Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial.

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.

P304

1-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1749-6632.2012.06670.X

http://www.w3.org/2001/XMLSchema#string

P407

P478

1263

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22823582

http://www.w3.org/2001/XMLSchema#string